Astrazeneca PLC (AZN) stock prices updated...
 

Astrazeneca PLC stock price

Astrazeneca PLC latest news:


  • 09/14/2017 14:48:30

    BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

    * Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

  • 09/10/2017 23:51:36

    UK Stocks-Factors to watch on Sept 11

    Sept 11 (Reuters) - Britain's FTSE 100 index is seen opening up 28 points at 7,405 on Monday, according to financial bookmakers. * AstraZeneca: Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease. * SHELL: Shell's Nigerian business has signed a $300 mln deal with Shoreline Energy to develop gas pipeline infrastructure in the country, Financial Ti

  • 09/09/2017 09:04:15

    AstraZeneca CEO, worried by Brexit, not signing UK government letter

    MADRID (Reuters) - AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government's strategy.

  • 09/08/2017 16:46:38

    AstraZeneca shares tick higher on lung cancer drug study results

    U.S. shares of AstraZeneca PLC rose in the extended session Friday after the drug maker released promising results from a lung cancer drug study. AstraZeneca American depositary receipts rose 2% to $32.90 after hours. The company said a late-stage clinical trial of its drug Tagrisso improved progression-free survival rates in certain lung cancer patients to a median 18.9 months compared with the 10.2 months seen in patients given standard of care treatment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/06/2017 23:36:22

    UK Stocks-Factors to watch on Sept 7

    Sept 7 (Reuters) - Britain's FTSE 100 index is seen opening 10 points higher at 7354.13 on Thursday, according to financial bookmakers. * RBS: Britain's financial regulator should release a leaked report about Royal Bank of Scotland that alleged many companies suffered from "inappropriate action" by its Global Restructuring Group unit, a senior British lawmaker said. * ASTRAZENECA: A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises t

  • 08/07/2017 12:15:00

    3 High-Yield Stocks for Aggressive Investors

    The high-yield dividend stocks AstraZeneca plc, GameStop, and Las Vegas Sands may be worth checking out right now.

  • 08/01/2017 00:38:12

    AstraZeneca gets breakthrough status for blood cancer drug

    LONDON, Aug 1 (Reuters) - AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

  • 07/31/2017 00:36:15

    AstraZeneca drug gets breakthrough status in early lung cancer

    AstraZeneca(AZN) said on Monday its immunotherapy drug Imfinzi had been granted "breakthrough" designation by U.S. regulators for treating non-metastatic lung cancer, following the success of the so-called Pacific trial.

  • 07/27/2017 15:15:31

    Facebook and Verizon advance while AstraZeneca dives

    Facebook and Verizon Communications trade higher while AstraZeneca and Southwest Airlines drop

  • 07/27/2017 10:43:43

    UPDATE 3-Bristol-Myers shares slump after failed AstraZeneca drug trial

    July 27 (Reuters) - Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen.

  • 07/27/2017 01:34:42

    AstraZeneca revenue down as key drugs lose patent protection

    Anglo-Swedish drugmaker AstraZeneca says second-quarter revenue fell amid declining sales of blockbuster drugs Crestor and Seroquel XR, which lost patent protection in the United States last year

  • 07/27/2017 01:28:18

    BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck

    Astrazeneca Plc(AZN): * ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION. * Astrazeneca Plc(AZN) - ASTRAZENECA AND MERCK WILL INDEPENDENTLY DEVELOP AND COMMERCIALISE LYNPARZA AND POTENTIAL MEDICINE SELUMETINIB IN COMBINATIONS WITH COMPANIES' RESPECTIVE. * MERCK WILL PAY CO UP TO $8.5 BILLION IN TOTAL CONSIDERATION.

  • 07/27/2017 01:27:20

    AstraZeneca drags down FTSE 100

    The drugmaker is the biggest loser on the index after its share price falls more than 15%.

  • 07/27/2017 00:33:33

    AstraZeneca lung cancer study fails in big setback for company

    AstraZeneca's(AZN) combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

  • 07/27/2017 00:33:15

    UPDATE 1-AstraZeneca lung cancer study fails in big setback for company

    LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

  • 07/27/2017 00:19:17

    AstraZeneca lung cancer drug combination misses goal in key study

    LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday. (Reporting by Ben Hirschler)

  • More trends:

    AT&T Inc.T | Atento S.A.ATTO | Atlantic Power CorporationAT | Atlas EnergyATLS | Atlas Resource PartnersARP | Atlas Resource PartnersARP^D | Atlas Resource PartnersARP^E | Atmos Energy CorporationATO | Atwood OceanicsATW | AU Optronics CorpAUO |